Mustang Bio (MBIO) Amortizatization of Intangibles (2016 - 2023)
Mustang Bio (MBIO) posted quarterly Amortizatization of Intangibles of -$25000.0 for Q2 2023, down 116.89% year-over-year from $148000.0 in Q2 2022, and down 117.48% quarter-over-quarter from $143000.0 in Q1 2023.
Mustang Bio (MBIO) Amortizatization of Intangibles (2016 - 2023) Analysis & Trends
Mustang Bio (MBIO) has reported Amortizatization of Intangibles for 5 consecutive years, with -$25000.0 the latest figure, recorded in Q2 2023.
- In Q2 2023, Amortizatization of Intangibles fell 116.89% year-over-year to -$25000.0; the TTM figure through Mar 2024 stood at -$25000.0 (down 104.34% YoY), while the FY2023 annual figure was $118000.0, down 74.89% from the prior year.
- Amortizatization of Intangibles declined to -$25000.0 in Q2 2023 per MBIO's latest filing, from $143000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.8 million in Q3 2020 and bottomed at -$25000.0 in Q2 2023.
- Historically, Amortizatization of Intangibles has averaged $300083.3 across 4 years, with a median of $190000.0 in 2019.
- Annual changes were most pronounced in 2020 — Amortizatization of Intangibles surged 665.81% — and 2023, when it tumbled 116.89%.
- Mustang Bio's Amortizatization of Intangibles stood at $244000.0 in 2019, then surged by 634.43% to $1.8 million in 2020, then sank by 92.08% to $142000.0 in 2022, then plunged by 117.61% to -$25000.0 in 2023.
- Business Quant data shows MBIO's Amortizatization of Intangibles at -$25000.0 in Q2 2023, $143000.0 in Q1 2023, and $142000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Mustang Bio | 3.90 Mn | 3.90 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -25,000.00 |
| Jun 30, 2023 | -25,000.00 |
| Mar 31, 2023 | 143,000.00 |
| Mar 31, 2023 | 143,000.00 |
| Dec 31, 2022 | 142,000.00 |
| Dec 31, 2022 | 142,000.00 |
| Sep 30, 2022 | 143,000.00 |
| Sep 30, 2022 | 143,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Jun 30, 2022 | 148,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Mar 31, 2022 | 19,000.00 |
| Sep 30, 2020 | 1.79 Mn |
| Sep 30, 2020 | 1.79 Mn |
| Jun 30, 2020 | 270,000.00 |
| Jun 30, 2020 | 270,000.00 |
| Mar 31, 2020 | 259,000.00 |
| Mar 31, 2020 | 259,000.00 |
| Dec 31, 2019 | 244,000.00 |
| Dec 31, 2019 | 244,000.00 |